Lakewood-Amedex Biotherapeutics Inc.
LABTNasdaq
$1.89
↑ +2.2%Jul 17 close · end-of-day
Price
1Y↓ -97.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$11,709.00
Return 1Y
—
Company profile
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Our corporate address is in University Park, Florida.
- CEO
- Kelvin Cooper
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Florida
- Website
- lakewoodamedex.com
Earnings
LABT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.20↑ +33.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2025 |
|---|---|
| Revenue | — |
| Gross profit | — |
| Operating income | — |
| Net income | — |
| Diluted EPS | — |
| Operating cash flow | — |
| Free cash flow | — |
| Gross margin | — |
| Operating margin | — |
| Net margin | — |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$542,609.00 | -$886,750.00 |
| Net income | -$539,617.00 | -$923,291.00 |
| Diluted EPS | -$0.15 | -$0.20 |
| Operating cash flow | -$404,089.00 | -$349,691.00 |
| Free cash flow | — | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
Company news
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.